These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 29921318

  • 1. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.
    Arthritis Res Ther; 2018 Jun 19; 20(1):129. PubMed ID: 29921318
    [Abstract] [Full Text] [Related]

  • 2. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.
    Arthritis Res Ther; 2016 Sep 06; 18(1):198. PubMed ID: 27600829
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.
    Ann Rheum Dis; 2017 May 06; 76(5):840-847. PubMed ID: 27856432
    [Abstract] [Full Text] [Related]

  • 4. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.
    J Rheumatol; 2019 Oct 06; 46(10):1259-1267. PubMed ID: 30877216
    [Abstract] [Full Text] [Related]

  • 5. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song IH, Enejosa J, Schlacher C, Song Y, Fleischmann R.
    Rheumatology (Oxford); 2021 Dec 01; 60(12):5583-5594. PubMed ID: 33590829
    [Abstract] [Full Text] [Related]

  • 6. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.
    J Rheumatol; 2012 Jan 01; 39(1):63-72. PubMed ID: 22045836
    [Abstract] [Full Text] [Related]

  • 7. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V, Boklage SH, Kimura T, Joly F, Boyapati A, Msihid J.
    Arthritis Res Ther; 2020 Oct 20; 22(1):250. PubMed ID: 33081825
    [Abstract] [Full Text] [Related]

  • 8. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.
    RMD Open; 2017 Oct 20; 3(1):e000416. PubMed ID: 28326189
    [Abstract] [Full Text] [Related]

  • 9. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC.
    Arthritis Res Ther; 2022 Jun 24; 24(1):155. PubMed ID: 35751108
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.
    Ann Rheum Dis; 2017 Nov 24; 76(11):1853-1861. PubMed ID: 28798049
    [Abstract] [Full Text] [Related]

  • 11. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.
    Arthritis Res Ther; 2019 Dec 02; 21(1):263. PubMed ID: 31791386
    [Abstract] [Full Text] [Related]

  • 12. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.
    Arthritis Res Ther; 2019 Dec 09; 21(1):272. PubMed ID: 31815649
    [Abstract] [Full Text] [Related]

  • 13. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3209-3221. PubMed ID: 33313898
    [Abstract] [Full Text] [Related]

  • 14. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B.
    Arthritis Res Ther; 2022 Jan 03; 24(1):11. PubMed ID: 34980223
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo WL, Won JE, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini CAF.
    Arthritis Res Ther; 2017 Sep 18; 19(1):208. PubMed ID: 28923098
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC.
    RMD Open; 2019 Sep 18; 5(2):e001017. PubMed ID: 31673415
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR.
    Arthritis Res Ther; 2020 Jun 10; 22(1):139. PubMed ID: 32522251
    [Abstract] [Full Text] [Related]

  • 18. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A.
    Arthritis Res Ther; 2020 Apr 07; 22(1):70. PubMed ID: 32264972
    [Abstract] [Full Text] [Related]

  • 19. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H.
    Arthritis Res Ther; 2019 Mar 20; 21(1):79. PubMed ID: 30894208
    [Abstract] [Full Text] [Related]

  • 20. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, Zwillich SH, Fleischmann R.
    Arthritis Res Ther; 2015 Nov 04; 17():307. PubMed ID: 26530039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.